Rigel Pharmaceuticals, Inc. 237.4% Potential Upside Now Implied by Piper Jaffray

Rigel Pharma

By spotting trends, moving averages allow investors to make those trends work in their favor and increase the number of winning trades.

A look at performance overview of Rigel Pharmaceuticals, Inc. depicts that Performance (Week) is 25.75 percent while Performance Month is 33.73%.

Rigel now has a Zacks Rank #3 (Hold). Finally, Jefferies Group reiterated a buy rating and set a $8.00 price target (down previously from $10.00) on shares of Rigel Pharmaceuticals in a research report on Monday, May 16th. The daily trading range was observed between a day's low price of $3.25 to a day's high price of $4.06.

TheStreet Ratings rated this stock as a "sell" with a ratings score of D. The $9.50 average target is 150.66% above today's ($3.79) stock price.

Several hedge funds recently made changes to their positions in RIGL.

DSW Inc. (NYSE:DSW) said that, its Board of Directors declared a quarterly cash dividend payment of $0.20 per share. HC Wainwright started coverage on shares of Rigel Pharmaceuticals in a report on Wednesday, July 13th. The Q4 2016 consensus earnings estimates for the company have stabilized at US$-0.22 per share. The stock traded with the volume of 12.76 Million in the last trading session. Finally, Metropolitan Life Insurance Co. Company is -37.38% away from its 52 week high and is moving 170.73% ahead of its 52 week low. Metropolitan Life Insurance Co. The company's stock is soaring, up more than 36% as of 11:15 a.m. EDT after management released encouraging data from Rigel's first FIT phase 3 clinical trial. Moreover, Palo Alto Investors Llc has 0.91% invested in the company for 5.39 million shares. The company's expenses rose to $22.3 million from $19.2 million in the year-ago period.

The stock is now trading at Distance from 20-Day simple moving Average of 16.69% whereas, Distance from 50-Day Simple moving average is 33.8 Percent and Distance from 200-Day Simple Moving Average of 28.79 percent. The 52 week high for the stock is 3.9 United States dollars while the year low share price is now 1.88 USD.

Rigel Pharmaceuticals, Inc.'s (RIGL) ended its day with a gain of 48.86% and finalized at the price of $3.93. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.05. The company could submit its NDA as soon as the first quarter of next year if data pan out from the second phase III test. During the same quarter in the prior year, the firm posted ($0.16) EPS.

Many Wall Street Analysts have commented on Rigel Pharmaceuticals.

A EVP, Pres. Discovery&Research at Rigel Pharmaceuticals, Inc. The Firm is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms.



Other news